Brad Richard Henke

This inventor holds 4 USPTO granted patents. Top assignees: Glaxo Wellcome Inc., Novatarg, Inc.. Active years: 1999-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brad Richard Henke. Retrieved from https://idiyas.com/inventor/brad-richard-henke-7bfjphzr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4

% Patents Active = 100.0

Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 23(Granted Patents)

Company Filing History:

Years Active: 1999-2023

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11834411 - Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy (2023-12-05),

2. 11261157 - Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy (2022-03-01),

3. 6294580 - Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma (2001-09-25),

4. 5859007 - CCK or gastrin modulating benzo �b!�1,4! diazepines derivatives (1999-01-12),

Title: The Innovations of Brad Richard Henke

Introduction

Brad Richard Henke is a notable inventor based in Cary, NC (US). He has made significant contributions to the field of medicinal chemistry, particularly through his innovative patents. With a total of four patents to his name, Henke's work focuses on novel compounds that have potential therapeutic applications.

Latest Patents

Henke's latest patents include the development of fused bicyclic alkylene linked imidodicarbonimidic diamides. These compounds are designed to be organic cation transporter selective compounds, which are believed to be useful in treating diseases and conditions associated with reduced activity of 5' adenosine monophosphate-activated protein kinase (AMPK). The specific compounds described in his patents include N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides.

Career Highlights

Throughout his career, Henke has worked with prominent companies in the pharmaceutical industry, including Glaxo Wellcome Inc. and Novatarg, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Henke has collaborated with notable colleagues such as Timothy Mark Willson and Marcus Brackeen. These partnerships have likely enhanced his research and development efforts in the field of medicinal chemistry.

Conclusion

Brad Richard Henke's contributions to the field of medicinal chemistry through his innovative patents demonstrate his commitment to advancing therapeutic solutions. His work continues to have a significant impact on the development of new treatments for various diseases.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]